Topical Imiquimod for Bowen's Disease of the Head and Neck

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Brooke Army Medical Center
ClinicalTrials.gov Identifier:
NCT00384124
First received: October 4, 2006
Last updated: March 25, 2008
Last verified: March 2008
  Purpose
  • Double blinded, randomized, placebo controlled trial of imiquimod for the treatment of histologically proven Bowens disease of the head and neck.
  • Null hypothesis: No difference in histologic clearance rates of patients with head or neck Bowens treated with imiquimod versus placebo.
  • Outcome: Histologic clearance of Bowens disease at T=14 weeks.

Condition Intervention Phase
Bowens Disease
Drug: Imiquimod
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks.

Resource links provided by NLM:


Further study details as provided by Brooke Army Medical Center:

Primary Outcome Measures:
  • histologic clearance of Bowens disease in treated versus placebo group [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: November 2006
Estimated Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Imiquimod
    Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
    Other Name: Aldara
Detailed Description:

Interventional study Enrolling

Inclusion criteria: Military beneficiaries with histologically proven Bowens disease, located on the head and neck, defined as any area superior to the clavicle and anterior to the posterior triangle of the neck

Exclusion Criteria:

  • Previous treatment of biopsied lesion Recurrent lesions from previous biopsy-proven Bowen's disease
  • Patients younger than 18 years of age
  • Pregnancy
  • Immunosuppression, including HIV, transplant patients on immune suppressive medications, cancer patients on chemotherapy, and hematologic malignancies (e.g., lymphoma, leukemia)
  • Mucous membrane involvement
  • Lesions larger than 2 cm

    • Methods: Pts randomized to treatment group (6 weeks of Mon-Friday Imiquimod to Bowens site) or vehicle group (same treatment regimen). All patients undergo surgical excision (Mohs or simple excision) of site where disease is either visible or was present and tissue examined for histologic evidence of residual Bowens disease
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic diagnosis of Bowen's disease (squamous cell carcinoma in situ), defined as full-thickness keratinocyte atypia and architectural disorder limited to the epidermis, with or without involvement of the follicular unit

    • Located on the head and neck, defined as any area superior to the clavicle and anterior to the posterior triangle of the neck
    • Primary Bowen's disease (first diagnosis)

Exclusion Criteria:

  • Previous treatment of biopsied lesion
  • Recurrent lesions from previous biopsy-proven Bowen's disease
  • Patients younger than 18 years of age
  • Pregnancy
  • Immunosuppression, including HIV, transplant patients on immune suppressive medications, cancer patients on chemotherapy, and hematologic malignancies (e.g., lymphoma, leukemia)
  • Mucous membrane involvement
  • Lesions larger than 2 cm
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00384124

Locations
United States, Texas
Brooke Army Medical Center Department of Dermatology
Fort Sam Houston, Texas, United States, 78234
Sponsors and Collaborators
Brooke Army Medical Center
Investigators
Principal Investigator: Nicole M Owens, MD Brooke Army Medical Center Department of Dermatology
  More Information

No publications provided

Responsible Party: Nicole Owens, MD, Brooke Army Medical Center Department of Dermatology
ClinicalTrials.gov Identifier: NCT00384124     History of Changes
Other Study ID Numbers: C.2005.087
Study First Received: October 4, 2006
Last Updated: March 25, 2008
Health Authority: United States: Federal Government

Keywords provided by Brooke Army Medical Center:
Bowens disease
Squamous cell carcinoma in situ of the skin
imiquimod

Additional relevant MeSH terms:
Bowen's Disease
Carcinoma
Carcinoma, Squamous Cell
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Imiquimod
Adjuvants, Immunologic
Antineoplastic Agents
Immunologic Factors
Interferon Inducers
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 21, 2014